Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of SAR441566 in moderate to severe plaque psoriasis
jRCT2061230086Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of balinatunfib in plaque psoriasis (6 arms), sponsored by Sanofi. Primary endpoint: PASI75 response at Week 12. Started Feb 2024; status: completed.
02
Drugs
balinatunfib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on jRCT2061230086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230086.